Research & Development

夜夜嚕2017最新在线2018天天看夜夜看狠狠看穞片山东公布首批社会力量设立科技奖励名单

發布時間︰

  雲瑯抱著閨女笑道︰“將軍住馬廄沒有什麼大不了的,以後說不定會成為美談。”   雲瑯神色難明的瞅著霍去病道︰“這可能很難!”夜夜嚕2017最新在线   或許,她當初因為一曲《鳳求凰》離開卓氏的時候有這樣的英氣……或許她在成都市上當壚賣酒的時候也有這樣的精氣神。2018天天看夜夜看   雲氏的車隊還沒有抵達陳倉,平遮派出的快馬卻先一步遇到了沈叛的車隊。   雲瑯搖搖頭道︰“他的負擔很重……所有人對他都有很高的期望,這讓他害怕了。”狠狠看穞片   “你會跟我走一遭的是吧?”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.


Connect? Registries


The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo